TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33439978
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe as ferrous fumarate with 2.8 mg folic acid
Study: 32885389
Drug: Non‐steroidal anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐steroidal anti‐inflammatory drugs (NSAIDs)
Study: 32885389
Drug: Combination biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination biologic therapy
Study: 35091727
Drug: Microneedle device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle device delivered topical steroids
Study: 35091727
Drug: Topical Daivobet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Daivobet gel (control)
Study: 32805133
Drug: Roux‐en‐Y gastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux‐en‐Y gastric bypass (RYGB) plus medical therapy (MT)
Study: 32544925
Drug: Kappa-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kappa-opioid receptor (KOR) antagonist for 8 weeks
Study: 32544925
Drug: Kappa-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kappa-opioid receptor (KOR) antagonist
Study: 33275278
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium
Study: 32192678
Drug: Chronic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic low level tragus stimulation (LLTS) at 20 Hz, 1 mA below discomfort threshold for 1 hour daily over 6 months
Study: 32448804
Drug: Camrelizumab combined
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab combined with apatinib (intermittent dosing)
Study: 38279575
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg BID
Study: 35226276
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg of elemental zinc daily for 24 weeks)
Study: 35585483
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (DEX)
Study: 616191571
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate prolonged release (previous treatment)
Study: 33010323
Drug: Ciclopiroxolamine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine 1% cream
Study: 36182235
Drug: Accelerated partner
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated partner therapy (usual care plus an offer of accelerated partner therapy)
Study: 36182235
Drug: Accelerated partner
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated partner therapy
Study: 35090531
Drug: OptiMA strategy
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMA strategy (ready-to-use therapeutic food at gradually tapered doses)
Study: 32912971
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment (oestradiol hemihydrate 10 μg vaginal pessaries)
Study: 32912971
Drug: No oestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oestrogen treatment
Study: 34064996
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of valine
Study: 34998508
Drug: i.v. TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. TXA 1 g
Study: 34998508
Drug: i.m. TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. TXA 1 g
Study: 34998508
Drug: oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral TXA solution 2 g
Study: 33571267
Drug: Iron containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron containing micronutrient powder supplementation (12.5 mg elemental iron, vitamin A 400 μg, ascorbic acid 30 mg, zinc 5 mg)
Study: 39271158
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH
Study: 32961500
Drug: One-day Acceptance
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day Acceptance and Commitment Therapy workshop
Study: 34292628
Drug: Promotility drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotility drug
Study: 32294244
Drug: L-PRF +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF + ABG
Study: 35984607
Drug: DOT Diary
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOT Diary (automated directly observed therapy)
Study: 35545995
Drug: delafloxacin 300
Normalized name: delafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: delafloxacin 300 mg
Study: 33609794
Drug: Janus‐kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janus‐kinase inhibitors
Study: 33175637
Drug: Conventional Salk‐IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Salk‐IPV (cIPV, 40:8:32 DU/dose)
Study: 34751757
Drug: Delayed surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surgical treatment
Study: 37056360
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy
Study: 36459369
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 µg/day 1 week before parathyroidectomy
Study: 36123858
Drug: COC2 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC2 (30 µg ethinyl estradiol/3 mg drospirenone)
Study: 35014049
Drug: mOIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOIT with total maintenance dose of 1200 mg protein
Study: 39548608
Drug: Mime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mime therapy
Study: 32173642
Drug: New wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: New wound dressing combined with Longxuejie capsules
Study: 32173642
Drug: Longxuejie capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longxuejie capsules (control group)
Study: 38241661
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine
Study: 33852164
Drug: Caffeine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (800 mg total, chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Study: 33852164
Drug: Placebo (chewed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Study: 38834226
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel (control)
Study: 32315497
Drug: Topical omiganan
Normalized name: Omiganan
DrugBank: Omiganan (DB06610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical omiganan 1%
Study: 36169979
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg per day) duration-response analysis
Study: 32265309
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam
Study: 32088913
Drug: Levetiracetam at
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam at 40 mg/kg over 10 min
Study: 32088913
Drug: Fosphenytoin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosphenytoin at 20 mg/kg phenytoin equivalents (PE)
Study: 34103179
Drug: cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cabazitaxel (20 or 25 mg/m2) in PROSELICA
Study: 33320753
Drug: Hydrocolloid/hydrogel dressings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid/hydrogel dressings plus 20 exposures to low-level laser therapy (LLLT)
Study: 36053806
Drug: Molnupiravir 400
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 400 mg every 12 hours for 5.5 days
Study: 36053806
Drug: Molnupiravir 800
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 800 mg every 12 hours for 5.5 days
Study: 36053806
Drug: Administration with
Normalized name: Blood Administration with Cair Clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration with food
Study: 32359044
Drug: Incremental cost-effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental cost-effectiveness ratios (ICER) moving from G‐BCT to S‐BCT
Study: 32359044
Drug: Percentage days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage days abstinent, adverse consequences of alcohol and drugs, overall relationship functioning
Study: 33851461
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (2 g)
Study: 33497362
Drug: Anti-CD40 monoclonal
Normalized name: Recombinant anti-CD40 monoclonal antibody
DrugBank: Lucatumumab (DB06360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine
Study: 33625518
Drug: Topical Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Timolol
Study: 34437553
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (various attributes assessed)
Study: 34437553
Drug: Food-drug interaction
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-drug interaction concern
Study: 32511774
Drug: Restricted dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Restricted dietary sodium intake (10 mmol/d, 230 mg/d)
Study: 36846138
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin
Study: 35192610
Drug: hsCRP 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP 2.0 to 4.9 mg/L
Study: 38307421
Drug: hsCRP <2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP <2 mg/L
Study: 34287833
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 20 mg/kg/day, titrated up to 30 mg/kg/day over 2 weeks
Study: 33455928
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (SGAs)
Study: 36146287
Drug: Real-time wearable
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time wearable feedback with daily goal using the Manumeter device for three weeks
Study: 35090543
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care physical therapy
Study: 32799922
Drug: tDCS+AMT (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS+AMT (15 min of concurrent tDCS and ankle motor tracking)
Study: 32482668
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment control group receiving only the therapeutic exercise protocol
Study: 35534916
Drug: G‐6‐PD‐deficient RBCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐6‐PD‐deficient RBCs
Study: 36305963
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges containing B. lactis HN019
Study: 34736563
Drug: FFR-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided treatment strategy
Study: 33515070
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (in children with the type 1 diabetes‐susceptible INS genotype)
Study: 36273202
Drug: Nalbuphine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 80 mg + 0.9% normal saline (72 ml) in patient-controlled analgesia pump
Study: 36273202
Drug: Morphine 80
Normalized name: MORPHINE 80MG/NALTREXONE 3.2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 80 mg
Study: 33167921
Drug: Activity-oriented proprioceptive
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-oriented proprioceptive antiedema therapy (TAPA)
Study: 33167921
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (Decongestive Lymphedema Therapy (DLT) or Complex Physical Therapy (CPT))
Study: 32840417
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles)
Study: 35120566
Drug: Minocycline 50
Normalized name: minocycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 50 mg orally, followed by 50 mg once a day for 5 days
Study: 32133487
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 2 g daily for 3 weeks
Study: 35377557
Drug: Transdiagnostic Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic Cognitive Behavioral Therapy (TCBT) during eight sessions provided by trained general health service providers
Study: 35437030
Drug: Acupuncture (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (12 treatment sessions over 4 weeks)
Study: 35437030
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (12 treatment sessions over 4 weeks)
Study: 32641335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different UF and sodium profiling strategies through individualised dialysate sodium concentration
Study: 35834252
Drug: mAb treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb treatment (casirivimab-imdevimab or sotrovimab)
Study: 33046611
Drug: Interaction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction of treatment allocation and WML severity
Study: 35896211
Drug: Oral imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral imatinib
Study: 34912506
Drug: 200 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL/day low-fat milk
Study: 34912506
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day pistachio
Study: 36000541
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (standard of care)
Study: 34229299
Drug: Core genes
Normalized name: Genesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core genes involved in regulation of extracellular matrix receptor interaction and chemotactic activity
Study: 35098820
Drug: High-dose amoxicillin-proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin-proton pump inhibitor dual therapy (20 mg esomeprazole four times daily and 750 mg amoxicillin four times daily for 14 days)
Study: 35098820
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (220 mg bismuth potassium citrate twice daily, 20 mg esomeprazole twice daily, 1000 mg amoxicillin twice daily, and 250 mg clarithromycin capsule twice daily for 14 days)
Study: 35098820
Drug: High-dose amoxicillin-proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin-proton pump inhibitor dual therapy
Study: 33902701
Drug: Guided online
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided online cognitive behavioral therapy for insomnia (i-Sleep)
Study: 33272333
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 international units) administered daily for 5 days
Study: 33272333
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 international units) administered every other day for 5 days
Study: 33837458
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression therapy (IPCT) with compression garment (CG) for 45 min, 3 times a week, for 4 weeks.
Study: 32211803
Drug: HFCM containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCM containing 6 g spice blend
Study: 32211803
Drug: HFCM with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCM with 0 g spice blend
Study: 34476776
Drug: Control (pseudo-treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (pseudo-treatment)
Study: 34478870
Drug: Mindfulness-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Therapy (MBT) consisting of eight weekly therapist-led, two-hour group sessions, and home practice (≥30 min/day, 6 days/week) during the 12-month study.
Study: 33398614
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) - transdermal: 980 nm, 200 mW, continuous, average energy fluency of 6 J/cm2 and intravenous: 405 nm, 1.5 mW, continuous for 30 min, applied before and after surgery for 6 days.
Study: 33970869
Drug: Norgestrel 75
Normalized name: levonorgestrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 75 mcg taken daily
Study: 33970869
Drug: Norgestrel 75
Normalized name: levonorgestrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 75 mcg taken 6 hours late
Study: 33970869
Drug: Norgestrel 75
Normalized name: levonorgestrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 75 mcg missed pill
Study: 35081255
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (SC)
Study: 33074192
Drug: Standard-of-care medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care medical therapy (MED)
Study: 39665575
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for metabolic acidosis
Study: 33458939
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy with completion of frequency volume charts regularly
Study: 33132658
Drug: Cap-assisted colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap-assisted colonoscopy (CC) in ulcerative colitis patients
Study: 33132658
Drug: Cap-assisted colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap-assisted colonoscopy (CC) during unsedated colonoscopy
Study: 33870426
Drug: G-tube feeding
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-tube feeding
Study: 38101433
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus platinum-based chemotherapy (group A)
Study: 38101433
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy (group C)
Study: 32416780
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy (group B)
Study: 34874514
Drug: Ubrogepant 50
Normalized name: ubrogepant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubrogepant 50 mg
Study: 37937851
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs)
Study: 35524444
Drug: Bumetanide as
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide as an adjunctive treatment
Study: 32086915
Drug: Tympanic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanic injection of dexamethasone
Study: 32086915
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration group
Study: 35363252
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion
Study: 36260947
Drug: Premature Infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature Infant Oral Motor Intervention (PIOMI) for 5 min/day for 14 days
Study: 35221304
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg/mL)
Study: 35221304
Drug: Adrenaline (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (0.01 mg/mL)
Study: 32920641
Drug: 5 doses
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 doses of 4.5 x 10^5 PfSPZ (Days 1, 3, 5, and 7; Week 16)
Study: 32920641
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 9.0 × 10^5 PfSPZ (Group 2)
Study: 32920641
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 18.0 × 10^5 PfSPZ (Group 3)
Study: 32920641
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 27.0 × 10^5 for dose 1 and 9.0 × 10^5 for doses 2 and 3 (Group 4)
Study: 33853109
Drug: Post-assessment survey
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-assessment survey regarding willingness to travel for treatment
Study: 34521217
Drug: Non-insulin-treated diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-treated diabetes
Study: 33234944
Drug: Insulin-treated diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-treated diabetes
Study: 33242251
Drug: Hourly staircase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly staircase sprint interval exercise (stair snacks)
Study: 38832504
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg thrice daily
Study: 32576287
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (Paracetamol/Orphenadrine combination)